While tirzepatide has yet to demonstrate direct cardiovascular risk outcomes in patients without type 2 diabetes, tirzepatide-treated groups did demonstrate reductions in cardiometabolic variables resulting in a significantly lower 10-year predicted ASCVD risk in patients with overweight or obesity without type 2 diabetes in post hoc analysis of the SURMOUNT-1 trial [49]
I am under 190 for the first time in six years
Kidney function significantly affects exenatide and lixisenatide clearance, but medications like semaglutide, tirzepatide, dulaglutide, and liraglutide undergo proteolytic degradation and do not require renal dose adjustments
What is the MinuteClinic Weight-Loss Program
SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit
Undoubtedly, the variants with an original PPH4 value exceeding 0.75 were considered conclusive evidence for colocalization [30]